Treatment group | n | Histology | P | LN Mets (%) | P | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|

Normal | PIN | WD | MD | PD | |||||||||

Castration + 5-aza | 19 | 58 | 5 | 0 | 0 | 37 | 21 | ||||||

PBS | 21 | 0 | 14 | 14 | 5 | 67 | <0.0001* | 43 | 0.19^{†} | ||||

5-Aza | 22 | 14 | 41 | 5 | 0 | 41 | 0.007^{‡} | 18 | 0.10^{§} | ||||

Castration | 19 | 30 | 0 | 0 | 0 | 70 | 0.19^{∥} | 37 | 0.29^{¶} |

Abbreviations: PIN, prostatic intraepithelial neoplasia; WD, well-differentiated prostate cancer; MD, moderately differentiated prostate cancer; PD, poorly-differentiated prostate cancer; LN, lymph node; Mets, metastasis.

↵* Fisher's exact test comparing the frequency of normal pathology between castration + 5-aza and PBS groups.

↵† Fisher's exact test comparing the frequency of lymph node metastasis between castration + 5-aza and PBS groups.

↵‡ Fisher's exact test comparing the frequency of normal pathology between castration + 5-aza and 5-aza groups.

↵§ Fisher's exact test comparing the frequency of lymph node metastasis between 5-aza and PBS groups.

↵∥ Fisher's exact test comparing the frequency of normal pathology between castration + 5-aza and castration groups.

↵¶ Fisher's exact test comparing the frequency of lymph node metastasis between castration and 5-aza groups.